Wutah pendapatan taun lumaku: Inhibrx Corp (INBX)

Logo perusahaan publik inhibrx.com (INBX)

The GURU.Markets terminal line chart, illustrating the year-over-year sales volume growth over the last 12 months, recorded a figure of 43.10. Inhibrx Biosciences (INBX) generates revenue based on royalties and payments from Sanofi for the drug INBRX-101. The company minimizes risks by developing protein-based therapies for cancer and rare pathologies, while enhancing drug discovery efficiency through the implementation of robotic screening systems.

Inhibrx Biosciences (INBX): Wutah pendapatan YoY sajrone 12 wulan kepungkur saka 11.02.2024 nganti 18.11.2026

Inhibrx Biosciences - rincian analitis lan metrik utama (INBX)

- rega saham lan target rega konsensus:
- indikator kapitalisasi bursa perusahaan:
Ringkesan analitik perusahaan:Inhibrx Biosciences Inc
Produk merek Inhibrx Corp

This indicator measures operational efficiency by recalculating annual revenue growth over a rolling period, allowing for an assessment of business scaling rates and asset stagnation risks. Since Inhibrx Biosciences (INBX) focuses on early-stage antibody development and lacks commercial sales, the comparative rolling year-over-year sales dynamics merely reflect the absence of current cash flow prior to the completion of clinical trials.

Karo sapa Inhibrx Biosciences saingan

Incyte Pharma - Wutah dodolan YoY sajrone rolas wulan kepungkur|HUTCHMED Corp - Wutah dodolan YoY (TTM)|Wutah pendapatan taun lumaku Nuvation Bio Inc.|DAWN: Wutah dodolan YoY (TTM)|Tingkat wutah pendapatan YoY sajrone rolas wulan kepungkur Monopar Pharma MNPR|Wutah pendapatan YoY sajrone 12 wulan kepungkur IMAB|Wutah pendapatan taun lumaku Fennec Pharmaceuticals FENC|Wutah pendapatan YoY sajrone 12 wulan kepungkur HRTX (Heron)|NVCT (Nuvectis Pharma) - Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Coherus Biosciences - Wutah pendapatan YoY sajrone 12 wulan kepungkur|Owah-owahan pendapatan YoY sajrone 12 wulan kepungkur CRBP (Corbus Pharmaceuticals Holdings)|Cardiff Oncology - Wutah dodolan YoY (TTM)|Dinamika pendapatan YoY sajrone rolas wulan kepungkur BYSI (BeyondSpring Pharma)|BCAB: Wutah dodolan YoY (TTM)|Wutah pendapatan taun lumaku lixte.com (LIXT)|Wutah dodolan YoY sajrone rolas wulan kepungkur citiuspharma.com|CLRB: Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Wutah dodolan YoY (TTM) BLRX|Wutah dodolan YoY (TTM) Can-Fite (CANF)|Wutah dodolan YoY sajrone rolas wulan kepungkur Aprea Therapeutics Inc. APRE|KZIA (kaziatherapeutics.com) - Wutah dodolan taun lumaku|SLXN: Wutah pendapatan YoY sajrone 12 wulan kepungkur|Wutah pendapatan taun lumaku NuCana|CMRX: Wutah dodolan YoY (TTM)|Wutah pendapatan YoY sajrone 12 wulan kepungkur Cyclacel Pharmaceuticals|GTHX (g1therapeutics.com) - Wutah dodolan YoY (TTM)|KRON: Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Wutah dodolan YoY sajrone rolas wulan kepungkur Kintara (KTRA)|Wutah pendapatan YoY sajrone 12 wulan kepungkur Oncternal ONCT|Portage Biotech - Wutah pendapatan YoY sajrone 12 wulan kepungkur